中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).

文献类型:期刊论文

作者Li, Peijing; Chen, Yuan Yuan Yuan; Lai, Shuzhen; Jiang, Fagui; Liu, Xiaohui; Tao, Changjuan; Wang, Lei; Liu, Guihong; Huang, Jing; Tang, Yiqiang
刊名JOURNAL OF CLINICAL ONCOLOGY
出版日期2021-05-20
卷号39
ISSN号0732-183X
DOI10.1200/JCO.2021.39.15_suppl.2039
WOS研究方向Oncology
语种英语
WOS记录号WOS:000708120600324
出版者LIPPINCOTT WILLIAMS & WILKINS
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/126698]  
专题中国科学院合肥物质科学研究院
作者单位1.Kecheng Dist Peoples Hosp, Quzhou, Peoples R China
2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
3.Shantou Univ, Guangdong YueBei Peoples Hosp, Shaoguan, Peoples R China
4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
5.Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
6.Nanjing Med Univ, Huaian Hosp 1, Huaian, Peoples R China
7.Nanchang Univ, Canc Hosp, Nanchang, Jiangxi, Peoples R China
8.Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
9.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
10.Maoming Peoples Hosp, Maoming, Peoples R China
推荐引用方式
GB/T 7714
Li, Peijing,Chen, Yuan Yuan Yuan,Lai, Shuzhen,et al. A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA Li, Peijing.,Chen, Yuan Yuan Yuan.,Lai, Shuzhen.,Jiang, Fagui.,Liu, Xiaohui.,...&Lu, Fangxiao.(2021).A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM)..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA Li, Peijing,et al."A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).".JOURNAL OF CLINICAL ONCOLOGY 39(2021).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。